Search results for " statins"

showing 10 items of 20 documents

Mevalonate pathway: role of bisphosphonates and statins.

2011

Mevalonate; statins; bisphosphonatesSettore MED/09 - Medicina InternaMevalonatestatinbisphosphonates
researchProduct

The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg)

2021

Statins could increase the effectiveness of Helicobacter pylori eradication therapies due to their anti-inflammatory effect. The aim of this study was to analyze the impact of this therapeutic association in real life. This is a multicenter, prospective, non-interventional study aimed at evaluating the management of H. pylori by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap from 2013 to 2020. The association between statin use and H. pylori eradication effectiveness was evaluated through multivariate analysis. Overall, 9988 and 705 patients received empirical and culture-guided treatment, respectively. Overall, statin use was associated with higher effecti…

Microbiology (medical)medicine.medical_specialtyMultivariate analysisHelicobacter pylori statins treatmentRM1-950BiochemistryMicrobiologyArticlestatinsRescue therapyInternal medicineIn real lifeMedicinePharmacology (medical)General Pharmacology Toxicology and Pharmaceuticsstatins ; Helicobacter pylori ; treatmentbiologyHelicobacter pyloritreatmentbusiness.industry<i>Helicobacter pylori</i>StatinStatin treatmentHelicobacter pyloribiology.organism_classificationTreatmentInfectious DiseasesTherapeutics. Pharmacologybusiness
researchProduct

Statins and angiogenesis in non-cardiovascular diseases.

2022

Statins inhibit HMG-CoA reductase by competitively inhibiting the active site of the enzyme, thus preventing cholesterol synthesis and reducing the risk of developing cardiovascular disease. Many pleiotropic effects of statins have been demonstrated that can be either related or unrelated to their cholesterol-lowering ability. Among these effects are their proangiogenic and antiangiogenic properties that could offer new therapeutic applications. In this regard, pro- and anti-angiogenic properties of statins have been shown to be dose dependent. Statins also appear to have a variety of non-cardiovascular angiogenic effects in many diseases, some examples being ocular disease, brain disease, …

PharmacologyCholesterolNeovascularization PathologicCardiovascular DiseasesNeoplasmsDrug DiscoveryHumansHydroxymethylglutaryl-CoA Reductase InhibitorsAngiogenesis Bone disease Brain disease Cancer Cardiovascular Diabetes Ocular disease Preeclampsia Statins VascularizationDrug discovery today
researchProduct

Venous Thrombosis Associated with HMG-CoA Reductase Inhibitors

2013

Abstract Among the various hypolipidemic drugs, 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (also known as "statins") belong to a heterogeneous class of compounds, sharing an identical hypocholesterolemic effect that develops through direct inhibition of a rate-limiting step in endogenous cholesterol synthesis. Their mechanism of action entails competitive inhibition of HMG-CoA reductase. Several lines of evidence suggest that the pleiotropic effects of statins may also play a role in prevention of venous thrombosis, wherein hypercholesterolemic patients are characterized by enhanced thrombin generation, increased susceptibility to endothelial dysfunction and plate…

Statinmedicine.drug_classHMG-CoA; statins; thrombosisPharmacologyReductaseRisk AssessmentstatinsHyperlipoproteinemia Type IIHMG-CoARisk FactorsmedicineHumansPlateletEndothelial dysfunctionthrombosisHypolipidemic AgentsVenous Thrombosisbiologybusiness.industryC-reactive proteinHematologymedicine.diseaseThrombosisVenous thrombosisHMG-CoA reductasebiology.proteinHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessSeminars in Thrombosis and Hemostasis
researchProduct

Mipomersen: a lipid-lowering agent with a novel mechanism of action

2013

“...mipomersen is a ... valuable alternative to apheresis for patients with heterozygous familial hypercholesterolemia.”

inorganic chemicalsLdl cholesterolChemistryEndocrinology Diabetes and MetabolismMipomersenLipid-lowering agentnutritional and metabolic diseasesPharmacologybehavioral disciplines and activitieshumanitiesantisense oligonucleotides LDL cholesterol lipid lowering mipomersen statinsApheresisMechanism of actionAntisense oligonucleotidesmedicineLipid loweringmedicine.symptomCardiology and Cardiovascular Medicinehealth care economics and organizationsClinical Lipidology
researchProduct

The Effects of Statin Treatment on Serum Ferritin Levels: A Systematic Review and Meta-Analysis.

2022

Background: Statins are the most widely used drugs for decreasing elevated serum LDL-cholesterol (LDL-C) and thus for the prevention of atherosclerotic cardiovascular disease (ASCVD), but they have also some pleiotropic effects, including anti-inflammatory properties. Atherosclerosis is a low-grade inflammatory disease, and elevated ferritin is considered to be one of the markers of inflammation. Since the results of studies on the effects of statins on serum ferritin levels are conflicting, this meta-analysis was performed. Methods: A literature search was performed using major electronic databases (MEDLINE/PubMed, Scopus, Embase, and ISI Web of Science) from inception up to 5 March 2022 t…

ironlipid-lowering therapyinflammationacute-phase response cardiovascular diseases inflammation iron lipid-lowering therapy statinsGeneral Medicineacute-phase responsecardiovascular diseasesstatinsJournal of clinical medicine
researchProduct

ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiova…

2017

Atherosclerotic cardiovascular disease still represents the leading cause of death in western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proven effective in improving clinical outcomes. This document is focused on the clinical management of hypercholesterolemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors have considered with particular attention the role of hypercholesterole…

medicine.medical_specialtySettore MED/09 - Medicina InternaPCSK9 inhibitorMEDLINE030204 cardiovascular system & hematologyNOatherosclerosis; diagnostic and therapeutic pathways; hypercholesterolaemia; PCSK9 inhibitors; statins; sustainable health careDiagnostic and therapeutic pathways03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicine030212 general & internal medicineIntensive care medicineRisk managementCause of deathHypercholesterolaemiabusiness.industryAtherosclerotic cardiovascular diseaseCholesterolSustainable health careStatinsDiagnostic and therapeutic pathwayStatinHigh Cholesterol LevelsArticlesmedicine.diseaseAtherosclerosischemistryPCSK9 inhibitorsAtherosclerosiCardiologylipids (amino acids peptides and proteins)Atherosclerosis; Diagnostic and therapeutic pathways; Hypercholesterolaemia; PCSK9 inhibitors; Statins; Sustainable health care; Cardiology and Cardiovascular MedicineCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal Supplements : Journal of the European Society of Cardiology
researchProduct

Rational for statin use in psoriatic patients

2013

Psoriasis represents a common skin disease which is clinically manifested by chronic cutaneous lesions. It has been observed that psoriasis is associated with an increased risk of cardiovascular diseases, which is contributed to the inappropriate lipid metabolism. Statins are commonly used in clinical practice to lower cholesterol concentration and, accordingly, decrease the individual risk of developing a cardiovascular episode. There have been reports that statin administration could also result in better management of psoriasis. The observed beneficial effects are contributed to the effects on lipid metabolism, including that in skin, as well as anti-inflammatory and immunomodulatory pro…

medicine.medical_specialtyStatinmedicine.drug_classAtorvastatinDermatologyDiseasePharmacologychemistry.chemical_compoundPsoriasisInternal medicinemedicineAnimalsHumansPsoriasiscardiovascular diseasesSkinCholesterolbusiness.industrynutritional and metabolic diseasesPsoriasis Statins Cholesterol Atorvastatin Fluvastatin SimvastatinGeneral Medicinemedicine.diseaseTreatment OutcomechemistrySimvastatinlipids (amino acids peptides and proteins)Dermatologic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPravastatinmedicine.drugFluvastatin
researchProduct

The Clinical Relevance of LDL Size and Subclasses Modulation in Patients with Type-2 Diabetes

2007

increasing evidence suggest that the "quality" rather than only the "quantity" of low density lipoproteins (LDL) exerts a great influence on the cardiovascular risk. Hypertriglyceridemia, low HDL-cholesterol and increased levels of small dense LDL characterise diabetic dyslipidemia. in subjects with type-2 diabetes LDL size seems also to represent a good marker of clinical apparent and non-apparent atherosclerosis. Recently, the Coordinating Committee of the National Cholesterol Education Program stated that high-risk patients may benefit of stronger therapeutical approaches, a category of subjects that include those with type-2 diabetes. Screening for the presence of small, dense LDL may p…

medicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismAtorvastatinPharmacologyEndocrinologyEzetimibeInternal medicineInternal MedicineHumansMedicineGemfibrozilCholesterol absorption inhibitorNational Cholesterol Education ProgramHypolipidemic Agentssmall dense LDL subclasses fibrates statins ezetimibe diabetes high-riskFenofibrateBezafibratebusiness.industryHypertriglyceridemiaGeneral Medicinemedicine.diseaseLipoproteins LDLMolecular WeightEndocrinologyDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)businessmedicine.drugExperimental and Clinical Endocrinology &amp; Diabetes
researchProduct

Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involvin…

2013

The available studies have reported the benefits of statins on all-cause and cardiovascular mortality in chronic kidney disease (CKD) patients. However studies in end-stage renal disease patients on dialysis yielded conflicting results. Therefore, we performed a meta-analysis and provide the most reliable trial data to date on the impact of statin therapy on cardiovascular events and death from all causes in CKD patients. Data from PubMed, Web of Science, Cochrane Library, and Scopus for the years 1966 to October 2012 were searched. The final meta-analysis included 11 randomized controlled trials involving 21,295 participants with CKD. Among them 6857 were on dialysis. The use of statins in…

medicine.medical_specialtymedicine.medical_treatmentDiseaseCochrane Librarylaw.inventionRandomized controlled triallawRenal DialysisInternal medicinemedicineHumansRenal Insufficiency ChronicIntensive care medicineDialysisRandomized Controlled Trials as TopicPharmacologybusiness.industrymedicine.diseaseConfidence intervalCardiovascular events Chronic kidney disease Dialysis Mortality Statins StrokeStrokeCardiovascular DiseasesMeta-analysisRelative riskHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessKidney diseasePharmacological research
researchProduct